Q2 2026 Novanta Inc Earnings Call Transcript
Key Points
- Novanta Inc (NOVT) delivered strong Q2 2026 results with 9% organic sales growth, 16% adjusted EBITDA growth, and 17% adjusted EPS growth, exceeding expectations.
- The company closed its largest acquisition, Riverpoint Medical, which is expected to be immediately accretive to revenue growth, gross margins, EBITDA margins, and EPS, while expanding medical end-market exposure to 60% of revenue.
- New product revenue surged over 50% in Q2 and over 60% year-to-date, lifting the vitality index to approximately 29% of sales, up from 21% a year ago.
- All four business units achieved organic growth in Q2, with strong momentum in precision robotics, physical AI, semiconductors, and minimally invasive surgery, supported by bookings up 18% year-to-date.
- Operating cash flow for the first half of 2026 already exceeded the full-year 2025 total, positioning the company for a record year in cash flow generation.
- The company raised its full-year 2026 guidance, expecting over 15% reported revenue growth and continued margin expansion, with gross margins projected to improve to 48% in Q3.
- The Medical Solutions segment experienced a book-to-bill of 0.79 in Q2, indicating weaker order intake relative to shipments, though management attributes this to timing of customer orders.
- Precision medicine business grew only 5% year-over-year, with life sciences exposure expected to remain a drag, and management does not expect sustained growth in this segment until 2027.
- Medical Solutions adjusted gross margins declined 290 basis points year-over-year due to a higher mix of lower-margin precision medicine products and temporary costs from operational transformation.
- The company faces ongoing headwinds from tariffs, particularly Section 232 and 301, which are not fully offset by surcharging, and inflationary pressures on supply chain and logistics.
- The integration of Riverpoint Medical introduces execution risks, including transition from a private to public company, with management adopting a conservative outlook for the acquired business's financial performance.
- The company is accelerating two additional factory closures, which could disrupt operations and incur temporary costs, though management expects long-term benefits.
Good morning. My name is Andrea, and I will be your conference operator today. At this time, I would like to welcome everyone to Novanta Incorporated second-quarter 2026 earnings call. (Operator Instructions) Please note this event is being recorded.
I would now like to turn the conference over to Marcy Meditz, Corporate Finance Leader for Novanta. Please go ahead.
Thank you very much. Good morning, and welcome to Novanta's second-quarter 2026 earnings conference call. This is Marcy Meditz, Corporate Finance Leader for Novanta. With me on today's call is our Chair and Chief Executive Officer, Matthijs Glastra; our Chief Financial Officer, Robert Buckley; and our Co-Chief Operating Officers, Chuck Ravetto and John Lesica. If you have not received a copy of our earnings press release issued last night, you may obtain it from the Investor Relations section of our website at www.novanta.com.
Please note, this call is being webcast
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
